Jyothy Labs Ltd.

Jyothy Labs has shown consistent growth in net sales and profitability, with net sales increasing from INR 1,711.17 crore in March 2020 to INR 2,846.98 crore in March 2025, and profit after tax rising from INR 162.58 crore to INR 370.38 crore in the same period. The company's total assets also grew significantly, reflecting its overall financial resilience.

As of November 7, 2025, Jyothy Labs is considered fairly valued with a PE ratio of 30.63 and an attractive valuation grade, but it has underperformed in the market with a year-to-date return of -21.62% compared to a 6.50% gain in the Sensex.

As of November 7, 2025, Jyothy Labs is considered fairly valued with a PE ratio of 30.63 and an attractive valuation compared to peers like Hindustan Unilever and Nestle India, despite a year-to-date return of -21.62% against the Sensex's 6.50%.

As of November 7, 2025, Jyothy Labs is considered fairly valued with a PE ratio of 30.63 and strong fundamentals, despite a year-to-date stock decline of -21.62%, positioning it attractively compared to peers like Hindustan Unilever and Nestle India.

As of November 6, 2025, Jyothy Labs is considered very attractive and undervalued in the FMCG sector, with strong operational efficiency indicated by a PE ratio of 30.81 and a PEG ratio of 0.00, making it a compelling investment opportunity despite recent underperformance against the Sensex.

Jyothy Labs has shown consistent growth in net sales and profits, with net sales increasing from ₹1,711.17 Cr in Mar'20 to ₹2,846.98 Cr in Mar'25, and profit after tax rising from ₹162.58 Cr to ₹370.38 Cr during the same period. The company also experienced significant growth in total assets and operating profit margins.

As of November 4, 2025, Jyothy Labs is considered overvalued with a valuation grade of attractive, reflected by a PE ratio of 31.12 and a significant underperformance of -37.87% compared to the Sensex's 5.94% return, despite being cheaper than peers like Hindustan Unilever and Nestle India.

As of November 4, 2025, Jyothy Labs is fairly valued with a PE ratio of 31.12 and strong profitability metrics, making it an attractive investment compared to more expensive peers like Hindustan Unilever and Nestle India, despite a year-to-date stock decline of 20.34%.

As of November 3, 2025, Jyothy Labs exhibits a mildly bearish trend, with mixed technical indicators showing a bearish stance in daily moving averages and KST, while the weekly MACD is mildly bullish, suggesting a cautious outlook overall.

As of October 31, 2025, Jyothy Labs is considered undervalued with a PE ratio of 30.94 and strong fundamentals, making it a compelling investment opportunity despite a year-to-date return of -20.82% compared to the Sensex's 7.42%.

As of October 31, 2025, Jyothy Labs is considered a very attractive investment opportunity due to its undervalued status, highlighted by a PE Ratio of 30.94, a PEG Ratio of 0.00, and a strong ROCE of 29.33%, despite recent underperformance compared to the Sensex.

As of October 31, 2025, Jyothy Labs is considered very attractive and undervalued, with a PE Ratio of 30.94, an EV to EBITDA of 22.05, and a ROCE of 29.33%, significantly lower than its peers Hindustan Unilever and Nestle India, despite a 39.89% decline in stock performance over the past year.

As of October 30, 2025, the market trend has shifted to bearish with moderate strength, indicated by daily moving averages and weekly KST and Bollinger Bands, despite mixed signals from the MACD across different time frames.

As of October 29, 2025, Jyothy Labs is considered fairly valued with a PE ratio of 31.56 and strong ROCE of 29.33%, but has underperformed year-to-date with a return of -19.22%, compared to the Sensex's gain of 8.78%.

Jyothy Labs has shown consistent growth in net sales and profits, with net sales increasing from 1,711.17 crore in March 2020 to 2,846.98 crore in March 2025, and profit after tax rising from 162.58 crore to 370.38 crore during the same period, while maintaining a zero debt status since March 2022.